Skip to main content
Equibles
LMMY logo

LMMY · Exousia Bio, Inc. · Documents

Track LMMY — free

Use LMMY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LMMY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.01 At close · Nov 11
Rebalance outlook locked
Going-concern doubt — flagged Jun 16, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The Company has accumulated deficit from inception (January 31, 2022) to February 28, 2026, of $288,623. These factors among others raise substantial doubt about the ability of the company to continue as a going concern for a reasonable period of time.”
View the 10-Q filed Jun 16, 2026
Market Cap
$635,250
Shares
52.50M
Volume · Nov 11 14.18K Avg daily vol (3M) 84.51K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $3750 down 67.4% 10-K filed Oct 17, 2025 Quarterly report Ended Feb 28, 2026 Revenue $0 10-Q filed Jun 16, 2026
2026
Mar 17
Quarterly report 10-Q FY2026 Q2, ended Nov 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $0 Net loss $19.08K Diluted EPS $0.00
2025
Oct 17
Annual report 10-K FY2025, ended May 31
Annual report for FY2025
Revenue $3750 ▼ 67.4% Net income $51.4K Diluted EPS $0.00
2024
Aug 30
Annual report 10-K FY2024, ended May 31
Annual report for FY2024
Revenue $11.5K Net loss $25.81K Diluted EPS $0.00
2023
2022
Showing 1–32 of 32 documents
Key facts CIK 1939937 CUSIP 50172J105 Visit website Investor relations